Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026

Same author

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026

Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026

Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026

Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026

Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026

Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026

Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026

Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 15, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

Low-grade gliomas.

Continuum (Minneapolis, Minn.)

|April 4, 2015

Summary

This summary is machine-generated.

Combining radiation and procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy offers the best survival for low-grade gliomas. Further research is needed to explore less toxic chemotherapy options and optimal treatment sequencing.

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Apr 15, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Area of Science:

Neuro-oncology
Oncology
Genetics

Background:

Low-grade gliomas present complex management challenges due to long survival and treatment toxicity concerns.
Tumor rarity complicates clinical trial design for optimal care strategies.
Isocitrate dehydrogenase (IDH) mutations are key diagnostic and prognostic markers in low-grade gliomas.

Purpose of the Study:

To review current management strategies for low-grade gliomas.
To evaluate the efficacy of different treatment modalities, including surgery, radiation, and chemotherapy.
To discuss the impact of IDH mutations on prognosis and treatment decisions.

Main Methods:

Review of recent clinical trials and scientific literature on low-grade glioma management.
Analysis of data supporting maximal safe tumor debulking.
Evaluation of comparative effectiveness of radiation therapy and chemotherapy regimens.

Main Results:

Maximal safe tumor debulking is increasingly supported as a first-line approach.
Chemotherapy shows comparable effectiveness to radiation therapy in preliminary studies.
A phase 3 trial demonstrated a significant survival advantage with combined radiation and procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy.

Conclusions:

Combined radiation and PCV chemotherapy provides the most effective survival benefit for low-grade gliomas currently.
Further investigation is required to assess the efficacy of temozolomide compared to PCV.
The potential benefits of upfront chemotherapy to mitigate radiation-induced cognitive toxicity warrant further study.